An observational study in Amyotrophic Lateral Sclerosis, sponsored by Royal Brompton & Harefield NHS Foundation Trust. Recruiting at 1 site in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-31.
Sponsored by Royal Brompton & Harefield NHS Foundation Trust · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 70 studies in Amyotrophic Lateral Sclerosis with a site in United Kingdom — 15 open to participants now, 22 under way, 6 of them phase 3. Amyotrophic Lateral Sclerosis · United Kingdom.
Among the 70 studies in Amyotrophic Lateral Sclerosis with a site in United Kingdom, this one is the 13th largest by planned enrollment of the 15 observational ones that give a count, is one of 7 that started in 2026, is one of 15 observational ones, reaches primary completion later than 9 of the 21 other live ones, and was the 66th registered.
981 studies on the registry are indexed under Amyotrophic Lateral Sclerosis; 280 are open to participants now.
Browse Amyotrophic Lateral Sclerosis studies →15 of the 70 studies in Amyotrophic Lateral Sclerosis with a site in United Kingdom are open now. Recruiting first, the newest first:
The Leeds Teaching Hospitals NHS Trust · Sites in United Kingdom
Ages 18+ · Healthy volunteers
Trace Neuroscience, Inc. · Sites in United Kingdom, Germany, Netherlands
Ages 18–75
NHS Greater Glasgow and Clyde · Sites in United Kingdom
Ages 18+
Prilenia · Sites in United Kingdom, United States, Belgium and 10 more countries
Ages 18–80
Vector Y Therapeutics · Sites in United Kingdom, United States, Belgium and 1 more country
Ages 18+
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 194 Amyotrophic Lateral Sclerosis studies recruiting now, 119 (61%) set no upper age limit and 23 (12%) stop at 75 or younger; 15 take children under 18; 56 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
70 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 19 · Phase 3 25
First in 2003; this study’s year is marked. 7 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 15 is below the median of 108 across 266 observational studies indexed under Amyotrophic Lateral Sclerosis.
Median enrollment 227 across the 55 interventional studies, 73 across the 15 observational. Of the 45 that completed or were terminated, 21 (47%) have results posted.
This tab as a report to print or save as PDF → With an account.
44 of 70 have an industry lead sponsor. The 10 most frequent:
Royal Brompton & Harefield NHS Foundation Trust is the lead sponsor of 141 studies on the registry; 21 are open to participants now.
Royal Brompton & Harefield NHS Foundation Trust has 1 study filed under Amyotrophic Lateral Sclerosis — fewer than ten, so there is no comparison to draw.
6 of the studies in Amyotrophic Lateral Sclerosis with a site in United Kingdom that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04856982Phase 3BiogenStudy to Learn If Tofersen (BIIB067) Can Delay ALS Symptoms and About Its Safety in Adults With a SOD1 Gene Mutation Who Have Not Yet Developed ALS Symptoms | 2027-08-07 |
| NCT07818772NHS Greater Glasgow and Clyde7T Imaging Pilot-study in Patients With Motor Neuron Disease to Find Non-Invasive Disease Imaging Biomarkers | 2026-11-30 |
| NCT07393932University of SheffieldMND Together: Phase 1 | 2026-12 |
| NCT07943442The Leeds Teaching Hospitals NHS TrustNovel MRI for an Earlier Diagnosis of Motor Neurone Disease | 2027-05-31 |
| NCT07674667Trace Neuroscience, Inc.FUNCtion ALS: Aiming to Restore UNC13A Function in People Living With ALS | 2027-09 |
Add all 6 to your calendar (.ics) → With an account.
Among the 70 studies in Amyotrophic Lateral Sclerosis with a site in United Kingdom, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The specific aim of this study is to try to discover the diagnostic accuracy of SleepImage technology for detecting respiratory failure in patients with MND. Importantly, this research project is not about NIV, it is about what method can most efficiently decide when to start NIV.
To do this we'd like to collect data about you and your breathing from the SleepImage device when you come in for your routine overnight sleep study. We will compare this against the data that we would collect anyway.
In general, where lung mechanics are normal, oxygen (O2) levels are the reciprocal of carbon dioxide (CO2) levels. However, due to the sigmoid shape of the oxygen dissociation curve peripheral capillary measurement of O2 (SpO2) via pulse oximeter does not provide adequate warning of respiratory failure in ALS. Advancements in sleep diagnostic equipment has allowed for the SleepImage System in addition to measuring SpO2, to also use tonometry to assesses autonomic output during sleep. SleepImage is US Food and Drug Administration, FDA-cleared and European Union Medical Device Regulatory EU-MDR compliant (CE-marked medical device). Specifically, SleepImage determines sleep architecture based on the strength of synchronisation between signals from the cardiovascular system (pulse rate variability) and respiratory system (tidal volume variability), based on cardiopulmonary coupling (CPC) analysis. Three distinct patterns of CPC are detected; (1) stable sleep (high-frequency coupling, HFC;0.1-0.4Hz) including all electroencephalogram estimated NREM-3 and part of NREM-2 sleep, associated with periods of stable breathing, non-cyclic alternating pattern (CAP) on the EEG, increased delta power and blood pressure dipping, (2) unstable sleep (low-frequency coupling, LFC;0.01-0.1Hz) including all NREM-1 and portion of NREM-2 associated with sleep instability, characterized by variability in tidal volumes, blood pressure non-dipping and CAP on EEG, (3) Wake and rapid eye movement (REM) sleep (very low-frequency coupling characteristics, vLFC;0-0.01Hz). The device can identify potential sleep pathologies evidenced by activity in a subset of unstable sleep where two discernible bands emerge; (1) a broad-spectral-band e-LFC (eLFCBB), linked to sleep fragmentation and obstructive sleep apnoea and (2) a narrow-spectral-band e-LCC (eLFCNB) in the frequency range 0.0006 to 0.1Hz, indicative of putative central sleep apnoea, periodic breathing or complex sleep apnoea. These metrics are expressed as a percentage of analysis windows related to the total sleep period. Other SleepImage diagnostic parameters include the Sleep Quality Index (SQI) which is biomarker and objective score of overall sleep quality. SQI integrates sleep stability, fragmentation, sleep duration and sleep pathologies derived from CPC and is presented on a scale of 0-100, apnoea hypopnea index , hypoxic burden , sleep onset, sleep offset, sleep duration, total sleep time , wake after sleep onset and sleep efficiency. At a practical level, the SleepImage device is a single patient, multiple use device which can be posted to the patient's home. It thus permits a sleep study assessment on as frequent as a basis as the physician and patient wish within the home setting.
The aim of this feasibility study is to review the efficacy of the SleepImage diagnostic equipment as a predictor of ventilatory impairment. This will be determined by a sleep quality index SQI of \<55 and Periodicity (eLFCNB) >2 showing an association with ventilatory failure.
The use of the SleepImage technology would not be to replace current diagnostic tests such as SNIP, VC, TcCO2 and blood gases, but instead used as an early screen tool. If a positive association can be made between SQI, Periodicity and ventilatory failure, then SleepImage technology could be used as a tool to expedite the process of hospital diagnostic tests to assess for ventilatory impairment. Furthermore, the SleepImage technology could be used once patients are established onto ventilation as a way of monitoring their ventilatory control on therapy.
Amyotrophic Lateral Sclerosis
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Device: SleepImage
SleepImage Device
SQI & e-LFCNB>2
We hypothesise that a SQI \<55 and Periodicity e-LFCNB\>2 has a positive association with an accepted indication for NIV initiation in ALS defined as: * Daytime Carbon Dioxide \>6.0kPa and a rise of \>1kPa from baseline in a time course consistent with REM sleep * Bicarbonate levels \>32mmol/L * SNIP \<40cmH20 in patients with non-bulbar disease * Supine fall in VC of 20% from erect in patient able to undertake the manoeuvre
Time frame: 12 hours
Hypoxic burden, T90, Pulse rate variability
The secondary endpoints of the study are to evaluate additional outputs generated by the SleepImage device and determine their association with the same established clinical criteria for NIV initiation in ALS. Specifically, the secondary analyses will focus on: * Hypoxic burden * SpO₂ time below 90% (T90). * Pulse rate variability
Time frame: 12 hours
Plan to share: Undecided
No publications or documents are linked to this record.
Started Mar 2026 (actual). Primary completion is estimated for Sep 2026, 5 months after the start.
Of 129 non-industry observational studies under Amyotrophic Lateral Sclerosis, half reached primary completion within 67 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 125. This study's planned 5 months is below that.
Counting every sponsor, half of 138 studies reached it within 64 months; a quarter within 29 and three quarters within 114.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Amyotrophic Lateral Sclerosis →
Royal Brompton & Harefield NHS Foundation Trust →